BASEL (dpa-AFX) - Sandoz, a Novartis company, announced the European Medicines Agency has accepted their Marketing Authorization Application for its biosimilar to Amgen's EU-licensed Neulasta. Sandoz is seeking approval for the same indication as the reference product.
Neulasta, or Pegfilgrastim, is a prescription medicine used in cancer patients to help with some of the side effects of their treatment.
Copyright RTT News/dpa-AFX